German science and technology giant Merck and the Korea Advanced Institute of Science and Technology (KAIST) will collaborate to accelerate progress in life sciences.
The scientific collaboration, culminating in a non-binding memorandum of understanding announced Thursday, aims to promote South Korea’s research and development ecosystem for industrial applications.
Through the partnership, Merck will supply products from its chemistry and biology portfolios to researchers in the laboratory.
The company will also provide development opportunities for KAIST researchers.
In addition, Merck and KAIST will set up an experience lab in Korea.
Matthias Heinzel, CEO of Merck, said that the “collaboration with KAIST is an important step towards accelerating the advance of biotechnology for both the local and global life science industries. Promoting research and preparing the next generation of scientists is key to discovering new medicines to meet needs.” of a world population – this is how we impact lives and health with science.”
In March, the company announced a €300 million ($324 million) investment in Korea to build a new bioprocessing production facility in Daejeon.
